Key Highlights

  • Net sales rose 30% to $35.5 million from $27.3 million.
  • Pharmacy channel sales rose 118% to $13.6 million.
  • Gross margin was 57.3%, up 179 basis points from 55.5%.
  • The net loss was $24.4 million, or $0.52 per share, against $14.2 million, or $0.33.
  • 2026 revenue is guided to $124 million to $126 million, with up to $8.5 million of deferral risk in the fourth quarter.

Beta Bionics Earnings: Why Could Mint Defer Up to $8.5 Million of Fourth-Quarter Revenue?

Beta Bionics (NASDAQ:BBNX) reported third-quarter results on Tuesday, October 27, with net sales of $35.5 million, up 30% from $27.3 million. Management narrowed 2026 revenue guidance to approximately $124 million to $126 million, from $121 million to $126 million.

The company said up to $8.5 million of fourth-quarter revenue could be deferred because prospective iLet users may wait for Mint, its next pump, which has FDA clearance. Management expects Mint to recapture that revenue in 2027, with full U.S. commercial launch in the first quarter.

Channel Mix: What Is Driving Growth in Pharmacy Sales?

Durable medical equipment channel sales rose 4% to $21.9 million. iLet pump sales in that channel fell to $11.6 million from $14.2 million, while single-use product sales rose to $10.3 million from $6.8 million.

The pharmacy channel produced $13.6 million, up 118% from $6.2 million, almost entirely single-use products. A high-30s share of new patient starts came through pharmacy, and full-year guidance of 37% to 39% is unchanged. New patient starts rose by a mid-single-digit percentage from the second quarter, and 69% came from multiple daily injections.

Margins and Losses: How Quickly Are Operating Expenses Rising?

Gross profit was $20.3 million, up from $15.1 million, and gross margin was 57.3%. Full-year gross margin guidance of 58.5% to 59.5% is unchanged,.

Operating expenses rose to $46.9 million from $32.2 million. Sales and marketing was $25.1 million against $16.0 million, research and development was $12.0 million against $8.2 million, and general and administrative expense was $9.8 million against $7.9 million. Loss from operations was $26.6 million, or 75% of sales, against $17.0 million.

The net loss was $24.4 million, or $0.52 per share on 46.5 million weighted shares, against $14.2 million, or $0.33. The screen's reported figure of negative $0.38 differs from the company's $0.52, and its estimate was negative $0.51 as screened. Adjusted EBITDA was a loss of $18.9 million, against $12.2 million.

Pipeline: Which Regulatory and Product Milestones Come Next?

The company withdrew a 510(k) for its 3D Intelligence dosing algorithm after FDA interactions. A revised submission with additional simulator validation data is planned for mid-fourth quarter, with launch in the first half of 2027 as iLet 3D and Mint 3D, or possibly in the fourth quarter if cleared.

Enrollment is complete in the U.S. pivotal trial of iLet in adults with type 2 diabetes, with an expanded indication expected around mid-2027 if cleared. A pivotal trial of a fully closed-loop algorithm, which removes meal announcements, is planned to start in the fourth quarter.

Mint manufacturing capacity of at least 1.5 million disposable units is expected in 2027. Integration with the Eversense 365 sensor system is expected to launch commercially in the fourth quarter.

Cash Position and What to Watch Next for Beta Bionics

Cash, cash equivalents and investments totaled $373.6 million at September 30, helped by net proceeds of about $161.3 million from a public offering. Shares outstanding rose to 54.4 million from 44.4 million at year-end 2025. Investors will track the 510(k) resubmission, the size of the Mint-related deferral, and the first-quarter 2027 launch.